Prezista (HIV) - Forecast and Market Analysis to 2022

Find Industry reports, Company profiles
ReportLinker and Market Statistics
>> Get this Report Now by email!

Prezista (HIV) - Forecast and Market Analysis to 2022
Published on January 2013

Report Summary


Summary

GlobalData has released its new PharmaPoint Drug Evaluation report, 'Prezista (HIV) - Forecast and Market Analysis to 2022'.
Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the
advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition
for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also
decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved
multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the
emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst
physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Prezista (darunavir) is an HIV PI that is co-administered with AbbVie's Norvir (ritonavir) in combination with other antiretroviral agents
for the treatment of HIV-infected patients. Prezista's mechanism of action involves selectively inhibiting the cleavage of HIV gag-pol
polyprotein, which prevents the formation of mature, infectious virus particles (Prezista prescribing information, 2012). Norvir is a
modest inhibitor of the HIV protease, but it mainly acts as a pharmacokinetic enhancer of Prezista. Ritonavir increases the plasma
levels of Prezista by inhibiting the cytochrome P450 enzyme CYP3A, which would otherwise decrease bioavailability and half-life of
Prezista via metabolism (Prezista prescribing information, 2012).

Scope

- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview
on the competitive landscape.
- Detailed information on Prezista including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Prezista for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Prezista performance
- Obtain sales forecast for Prezista from 2012-2022 in top nine countries (the US, France, Germany, Italy, Spain, the UK, Japan,
Brazil and China)

Prezista (HIV) - Forecast and Market Analysis to 2022 (From Slideshare) Page 1/5


Table of Content

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 13
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
3.2.1 Primary or Acute Infection 14
3.2.2 Chronic Infection 14
3.2.3 Advanced Infection/AIDS 15
4 Disease Management 16
4.1 Treatment Overview 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Prezista (darunavir) 23
6.1 Overview 23
6.2 Efficacy 24
6.3 Safety 25
6.4 SWOT Analysis 25
6.5 Forecast 27
7 Appendix 28
7.1 Bibliography 28
7.2 Abbreviations 31
7.3 Methodology 33
7.4 Forecasting Methodology 33
7.4.1 HIV Prevalence 33
7.4.2 Percent Drug-Treated Patients 33
7.4.3 General Pricing Assumptions 34
7.4.4 Individual Drug Assumptions 35
7.4.5 Generic Erosion 35
7.5 Physicians and Specialists Included in this Study 36
7.5.1 Survery of Prescribing Physicians 37
7.6 About the Authors 37
7.6.1 Authors 37
7.6.2 Global Head of Healthcare 38
7.7 About GlobalData 39



7.8 Contact Us 39
7.9 Disclaimer 39

List of Tables

Table 1: Symptoms HIV 15
Table 2: Treatment Guidelines for HIV 17
Table 3: Most Prescribed Drugs for HIV by Class in the Global Markets, 2012 18
Table 4: Leading Treatments for HIV, 2012 22
Table 5: Product Profile ' Prezista 24
Table 6: Prezista SWOT Analysis, 2012 26
Table 7: Global Sales Forecasts ($m) for Prezista, 2012-2022 27
Table 8: Physicians Surveyed, By Country 37

List of Figures

Figure 1: HIV Lifecycle 11


Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to:
Europe, Middle East and Africa : + 33 4 37 37 15 56
Asia, Oceania and America : + 1 (805) 617 17 93
If you have any questions please visit http://www.reportlinker.com/notify/contact

Order Information
Please verify that the product information is correct and select the format(s) you require.


Product Formats
Please select the product formats and the quantity you require.

1 User License--USD 6 995.00 Quantity: _____

Site License--USD 13 990.00 Quantity: _____

Corporate License--USD 20 985.00 Quantity: _____

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr Mrs Dr Miss Ms Prof

First Name: _____________________________ Last Name: __________________________________

Email Address: __________________________________________________________________________

Job Title: __________________________________________________________________________

Organization: __________________________________________________________________________

Address: __________________________________________________________________________

City: __________________________________________________________________________

Postal / Zip Code: __________________________________________________________________________

Country: __________________________________________________________________________

Phone Number: __________________________________________________________________________

Fax Number: __________________________________________________________________________


Payment Information
Please indicate the payment method, you would like to use by selecting the appropriate box.

Payment by credit card Card Number: ______________________________________________

Expiry Date __________ / _________

CVV Number _____________________

Card Type (ex: Visa, Amex…) _________________________________

Payment by wire transfer Crédit Mutuel
RIB : 10278 07314 00020257701 89
BIC : CMCIFR2A
IBAN : FR76 1027 8073 1400 0202 5770 189

Payment by check UBIQUICK SAS
16 rue Grenette – 69002 LYON, FRANCE

Customer signature:

Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at
http://www.reportlinker.com/index/terms

Please fax this form to:

Europe, Middle East and Africa : + 33 4 37 37 15 56

Asia, Oceania and America : + 1 (805) 617 17 93


Prezista (HIV) - Forecast and Market Analysis to 2022

Recomendados

Recomendados

Mais conteúdo relacionado

Mais de ReportLinker.com

Mais de ReportLinker.com (20)

Prezista (HIV) - Forecast and Market Analysis to 2022